
Jian-Chuan Xia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3002488/publications.pdf Version: 2024-02-01



ΙΙΔΝ-ΟΗΠΑΝ ΧΙΔ

#	Article	IF	CITATIONS
1	Impaired bone marrow microenvironment and stem cells in transfusion-dependent beta-thalassemia. Biomedicine and Pharmacotherapy, 2022, 146, 112548.	5.6	3
2	CMTM6 inhibits tumor growth and reverses chemoresistance by preventing ubiquitination of p21 in hepatocellular carcinoma. Cell Death and Disease, 2022, 13, 251.	6.3	20
3	CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype. , 2022, 10, e004029.		44
4	Cancerâ€Associated Fibroblastâ€Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma Progression. Hepatology, 2021, 73, 1717-1735.	7.3	147
5	Identification of Key Genes With Differential Correlations in Lung Adenocarcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 675438.	3.7	14
6	Neoadjuvant combination of pazopanib or axitinib and programmed cell death protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy may facilitate surgery in patients with renal cell carcinoma. Translational Andrology and Urology, 2021, 10, 2091-2102.	1.4	3
7	The efficacy and safety of the combination of axitinib and pembrolizumabâ€activated autologous DCâ€CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study. Clinical and Translational Immunology, 2021, 10, e1257.	3.8	4
8	Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatin. Cell Death and Disease, 2021, 12, 1093.	6.3	9
9	Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma. Journal of Hematology and Oncology, 2020, 13, 2.	17.0	36
10	Severe delayed pulmonary toxicity following PDâ€L1–specific CARâ€T cell therapy for nonâ€small cell lung cancer. Clinical and Translational Immunology, 2020, 9, e1154.	3.8	12
11	Annexin A3 upregulates the infiltrated neutrophil-lymphocyte ratio to remodel the immune microenvironment in hepatocellular carcinoma. International Immunopharmacology, 2020, 89, 107139.	3.8	11
12	Galectin-3 favours tumour metastasis via the activation of β-catenin signalling in hepatocellular carcinoma. British Journal of Cancer, 2020, 123, 1521-1534.	6.4	41
13	Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients with colorectal cancer after radical resection. Oncolmmunology, 2020, 9, 1752563.	4.6	15
14	<p>The Roles of Ubiquitination Factor E4B (UBE4B) in the Postoperative Prognosis of Patients with Renal Cell Carcinoma and in Renal Tumor Cells Growth and Metastasis</p> . OncoTargets and Therapy, 2020, Volume 13, 185-197.	2.0	5
15	Retrospective analysis of the efficacy of cytokineâ€induced killer cell immunotherapy combined with firstâ€line chemotherapy in patients with metastatic colorectal cancer. Clinical and Translational Immunology, 2020, 9, e1113.	3.8	12
16	CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2020, 69, 825-834.	4.2	14
17	<p>IL-37 induces anti-tumor immunity by indirectly promoting dendritic cell recruitment and activation in hepatocellular carcinoma</p> . Cancer Management and Research, 2019, Volume 11, 6691-6702.	1.9	24
18	PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer. , 2019, 7, 228.		26

#	Article	IF	CITATIONS
19	Low-Dose IFNγ Induces Tumor Cell Stemness in Tumor Microenvironment of Non–Small Cell Lung Cancer. Cancer Research, 2019, 79, 3737-3748.	0.9	89
20	<i>TES</i> functions as a Menaâ€dependent tumor suppressor in gastric cancer carcinogenesis and metastasis. Cancer Communications, 2019, 39, 1-14.	9.2	7
21	Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy. Oncolmmunology, 2019, 8, e1528411.	4.6	16
22	PD-L1 expression patterns in tumour cells and their association with CD8 ⁺ tumour infiltrating lymphocytes in clear cell renal cell carcinoma. Journal of Cancer, 2019, 10, 1154-1161.	2.5	18
23	Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer. Journal of Immunotherapy, 2019, 42, 284-296.	2.4	48
24	HUS1 checkpoint clamp component (HUS1) is a potential tumor suppressor in primary hepatocellular carcinoma. Molecular Carcinogenesis, 2019, 58, 76-87.	2.7	9
25	Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors. Oncolmmunology, 2018, 7, e1417721.	4.6	33
26	IL-17 induces antitumor immunity by promoting beneficial neutrophil recruitment and activation in esophageal squamous cell carcinoma. OncoImmunology, 2018, 7, e1373234.	4.6	47
27	Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma. Cancer Management and Research, 2018, Volume 10, 6457-6468.	1.9	23
28	SKA1 overexpression is associated with poor prognosis in hepatocellular carcinoma. BMC Cancer, 2018, 18, 1240.	2.6	28
29	Clinical Effect of Adjuvant Cytokine-Induced Killer Cells Immunotherapy in Patients with Stage II-IVB Nasopharyngeal Carcinoma after Chemoradiotherapy: A propensity score analysis. Journal of Cancer, 2018, 9, 4204-4214.	2.5	4
30	Weekly versus triweekly cisplatin plus intensity-modulated radiotherapy in locally advanced nasopharyngeal carcinoma: A propensity score analysis with a large cohort. Journal of Cancer, 2018, 9, 3447-3455.	2.5	11
31	Dendriticâ€cellâ€based immunotherapy evokes potent antiâ€tumor immune responses in CD105+ human renal cancer stem cells. Molecular Carcinogenesis, 2017, 56, 2499-2511.	2.7	14
32	Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes. Oncolmmunology, 2017, 6, e1312240.	4.6	68
33	Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC. BMC Cancer, 2017, 17, 412.	2.6	24
34	Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer. Chinese Journal of Cancer, 2017, 36, 77.	4.9	26
35	Immunization-based scores as independent prognostic predictors in soft tissue sarcoma patients. Journal of Cancer, 2017, 8, 606-616.	2.5	3
36	Overexpression of SMOC2 Attenuates the Tumorigenicity of Hepatocellular Carcinoma Cells and Is Associated With a Positive Postoperative Prognosis in Human Hepatocellular Carcinoma. Journal of Cancer, 2017, 8, 3812-3827.	2.5	16

#	Article	IF	CITATIONS
37	Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer. PLoS ONE, 2017, 12, e0174037.	2.5	12
38	Decreased TPD52 expression is associated with poor prognosis in primary hepatocellular carcinoma. Oncotarget, 2016, 7, 6323-6334.	1.8	21
39	The clinical significance of preoperative serum cholesterol and high-density lipoprotein-cholesterol levels in hepatocellular carcinoma. Journal of Cancer, 2016, 7, 626-632.	2.5	51
40	The expression and prognostic value of protein tyrosine kinase 6 in early-stage cervical squamous cell cancer. Chinese Journal of Cancer, 2016, 35, 54.	4.9	7
41	Evaluation of the immunogenicity of ALDHhigh human head and neck squamous cell carcinoma cancer stem cells in vitro. Oral Oncology, 2016, 59, 30-42.	1.5	23
42	Therapeutic Efficacy of Cancer Stem Cell Vaccines in the Adjuvant Setting. Cancer Research, 2016, 76, 4661-4672.	0.9	62
43	PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. OncoImmunology, 2016, 5, e1176653.	4.6	59
44	Expression and prognostic role of ubiquitination factor E4B in primary hepatocellular carcinoma. Molecular Carcinogenesis, 2016, 55, 64-76.	2.7	24
45	A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. Oncolmmunology, 2016, 5, e1083671.	4.6	56
46	Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma. Oncotarget, 2016, 7, 16248-16261.	1.8	28
47	IL-17A promotes migration and tumor killing capability of B cells in esophageal squamous cell carcinoma. Oncotarget, 2016, 7, 21853-21864.	1.8	31
48	Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis. Oncotarget, 2016, 7, 26670-26679.	1.8	51
49	A Nomogram for Predicting the Benefit of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Hepatocellular Carcinoma. Scientific Reports, 2015, 5, 9202.	3.3	22
50	Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma. Molecular Carcinogenesis, 2015, 54, 598-607.	2.7	53
51	Cancer stem cell vaccine inhibits metastases of primary tumors and induces humoral immune responses against cancer stem cells. Oncolmmunology, 2015, 4, e990767.	4.6	86
52	Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Oncolmmunology, 2015, 4, e976507.	4.6	61
53	Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer. Oncolmmunology, 2015, 4, e1038017.	4.6	14
54	Promise of cancer stem cell vaccine. Human Vaccines and Immunotherapeutics, 2015, 11, 2796-2799.	3.3	14

#	Article	IF	CITATIONS
55	Annexin A3 as a Potential Target for Immunotherapy of Liver Cancer Stem-Like Cells. Stem Cells, 2015, 33, 354-366.	3.2	54
56	Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma. PLoS ONE, 2015, 10, e0130620.	2.5	21
57	A novel pathogenic germline mutation in the adenomatous polyposis coli gene in a Chinese family with familial adenomatous coli. Oncotarget, 2015, 6, 27267-27274.	1.8	9
58	A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma. Oncotarget, 2015, 6, 41339-41349.	1.8	79
59	Protein kinase CK2α catalytic subunit is overexpressed and serves as an unfavorable prognostic marker in primary hepatocellular carcinoma. Oncotarget, 2015, 6, 34800-34817.	1.8	46
60	Overexpression of WWP1 Promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma. Oncotarget, 2015, 6, 40920-40933.	1.8	27
61	Decreased Expression of the GATA3 Gene Is Associated with Poor Prognosis in Primary Gastric Adenocarcinoma. PLoS ONE, 2014, 9, e87195.	2.5	11
62	Reduced Expression of Uroplakin 1A Is Associated with the Poor Prognosis of Gastric Adenocarcinoma Patients. PLoS ONE, 2014, 9, e93073.	2.5	12
63	Characterization of a Novel Transgenic Mouse Tumor Model for Targeting HER2+ Cancer Stem Cells. International Journal of Biological Sciences, 2014, 10, 25-32.	6.4	12
64	The phenotype of ex vivo generated cytokine-induced killer cells is associated with overall survival in patients with cancer. Tumor Biology, 2014, 35, 701-707.	1.8	20
65	OKâ€432 synergizes with IFNâ€Î³ to confer dendritic cells with enhanced antitumor immunity. Immunology and Cell Biology, 2014, 92, 263-274.	2.3	3
66	Decreased expression of TRIM3 is associated with poor prognosis in patients with primary hepatocellular carcinoma. Medical Oncology, 2014, 31, 102.	2.5	25
67	Decreased ITIH5 expression is associated with poor prognosis in primary gastric cancer. Medical Oncology, 2014, 31, 53.	2.5	12
68	Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast Cancer. Clinical Cancer Research, 2014, 20, 3003-3011.	7.0	68
69	Interleukin-37 Mediates the Antitumor Activity in Hepatocellular Carcinoma: Role for CD57+ NK Cells. Scientific Reports, 2014, 4, 5177.	3.3	93
70	The Efficacy of Cytokine-Induced Killer Cell Infusion as an Adjuvant Therapy for Postoperative Hepatocellular Carcinoma Patients. Annals of Surgical Oncology, 2013, 20, 4305-4311.	1.5	68
71	Decreased expression of interleukin-36α correlates with poor prognosis in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2013, 62, 1675-1685.	4.2	35
72	Cytokine-induced Killer Cells in Combination With Transcatheter Arterial Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Patients. Journal of Immunotherapy, 2013, 36, 287-293.	2.4	61

#	Article	IF	CITATIONS
73	Decreased Expression of Transcription Elongation Factor A-Like 7 Is Associated with Gastric Adenocarcinoma Prognosis. PLoS ONE, 2013, 8, e54671.	2.5	12
74	Effect of anti-asthma Chinese medicine Chuankezhi on the anti-tumor activity of cytokine-induced killer cells. Chinese Journal of Cancer, 2013, 32, 553-60.	4.9	8
75	Decreased Expression of the FOXO3a Gene Is Associated with Poor Prognosis in Primary Gastric Adenocarcinoma Patients. PLoS ONE, 2013, 8, e78158.	2.5	45
76	Autologous Cytokine-induced Killer Cell Transfusion in Combination With Gemcitabine Plus Cisplatin Regimen Chemotherapy for Metastatic Nasopharyngeal Carcinoma. Journal of Immunotherapy, 2012, 35, 189-195.	2.4	47
77	Involvement of hepatitis B virus X gene (HBx) integration in hepatocarcinogenesis via a recombination of HBx/ <i>Alu</i> core sequence/subtelomeric DNA. FEBS Letters, 2012, 586, 3215-3221.	2.8	13
78	Decreased expression of Vâ€set and immunoglobulin domain containing 1 (VSIG1) is associated with poor prognosis in primary gastric cancer. Journal of Surgical Oncology, 2012, 106, 286-293.	1.7	19
79	The Prognostic Value of Tumor-Infiltrating Neutrophils in Gastric Adenocarcinoma after Resection. PLoS ONE, 2012, 7, e33655.	2.5	104
80	Decreased Expression of the ARID1A Gene Is Associated with Poor Prognosis in Primary Gastric Cancer. PLoS ONE, 2012, 7, e40364.	2.5	85
81	Poor Prognosis of Gastric Adenocarcinoma with Decreased Expression of AHRR. PLoS ONE, 2012, 7, e43555.	2.5	16
82	Decreased expression of XPO4 is associated with poor prognosis in hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 544-549.	2.8	24
83	Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma. International Journal of Cancer, 2011, 128, 771-777.	5.1	33
84	The Accumulation and Prognosis Value of Tumor Infiltrating IL-17 Producing Cells in Esophageal Squamous Cell Carcinoma. PLoS ONE, 2011, 6, e18219.	2.5	118
85	Reduced Expression of Transcription Factor AP-2α Is Associated with Gastric Adenocarcinoma Prognosis. PLoS ONE, 2011, 6, e24897.	2.5	35
86	Identification of LZAP as a New Candidate Tumor Suppressor in Hepatocellular Carcinoma. PLoS ONE, 2011, 6, e26608.	2.5	38
87	Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells. Cancer Biology and Therapy, 2010, 10, 368-375.	3.4	31
88	Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation. Cancer Biology and Therapy, 2010, 9, 903-907.	3.4	39
89	Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK. Chinese Journal of Cancer, 2010, 29, 641-648.	4.9	36
90	Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses. Cancer Immunology, Immunotherapy, 2009, 58, 1587-1597.	4.2	38

#	Article	IF	CITATIONS
91	Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2008, 134, 1247-1253.	2.5	149
92	Decreased expression of ING2 gene and its clinicopathological significance in hepatocellular carcinoma. Cancer Letters, 2008, 261, 183-192.	7.2	54
93	Minimally Invasive Treatment Combined With Cytokine-induced Killer Cells Therapy Lower the Short-term Recurrence Rates of Hepatocellular Carcinomas. Journal of Immunotherapy, 2008, 31, 63-71.	2.4	150
94	Loss of heterozygosity analysis of a candidate gastric carcinoma tumor suppressor locus at 7q31. Cancer Genetics and Cytogenetics, 2006, 166, 166-172.	1.0	5